SEARCH

SEARCH BY CITATION

References

  • 1
    Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: modulator of renal function and presser resistance in chronic liver disease. J Clin Endocr Metab 1979; 48: 895900.
  • 2
    Bruix JJ, Bopsch D, Kravetz R, Mastai R, Rodes J. Effects of prostaglandin inhibition of systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985; 84: 430435.
  • 3
    Guarner F, Guarner C, Prieto J, Colina I, Quiroga J, Casas J, et al. Increased synthesis of systemic prostaglandin in cirrotic patients. Gastroenterology 1986; 90: 687694.
  • 4
    Moore K, Ward PS, Taylor GW, Williams R. Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Gastroenterology 1991; 100: 10691077.
  • 5
    Vishwanath BS, Frey FJ, Escher G, Reichen J, Frey BM. Liver cirrhosis induces renal and liver phospholipase A2 activity in rats. J Clin Invest 1996; 98: 365371.
  • 6
    Crowl RM, Stoller TJ, Conroy RR, Stoner CR. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem 1991; 266: 26472651.
  • 7
    Arbibe L, Vial D, Rosinski-Chupin I, Havet N, Huerre M, Vargaftig BB, et al. Endotoxin induces expression of type II phospholipase A2 in macrophages during acute lung injury in guinea pigs: involvement of TNF-alpha in lipopolysaccharide-induced type II phospholipase A2 synthesis. J Immunol 1997; 159: 391400.
  • 8
    Prytz H, Holst-Christensen J, Korner B, Liehr H. Portal venous and systemic endotoxemia in patients without liver disease and systemic endotoxemia in patients with cirrhosis. Scand J Gastroenterol 1976; 11: 857863.
  • 9
    Clemente C, Bosch J, Rodes J, Arroyo V, Mas A, Maragall S. Functional renal failure and hemorrhagic gastritis associated with endotoxemia in cirrhosis. Gut 1977; 18: 556560.
  • 10
    Uemura M, Buchholz H, Kojima A, Keppler A, Hafkemeyer P, Fukui H, et al. Cysteinyl leukotrienes in the urine of patients with liver diseases. HEPATOLOGY 1994; 20: 804812.
  • 11
    Hashizume M, Inokuchi K, Tanaka K. The role of prostacyclin in patients with portal hypertension. Liver 1985; 5: 8993.
  • 12
    Endoh T, Tang Q, Denda A, Noguchi O, Kobayashi E, Tamura K, et al. Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. Carcinogenesis 1996; 17: 467475.
  • 13
    Denda A, Endoh T, Tang Q, Tsujiuchi T, Nakae D, Konishi Y. Prevention by inhibitors of arachidonic acid cascade of liver carcinogenesis, cirrhosis and oxidative DNA damage caused by a choline-deficient, L-amino acid-defined diet in rats. Mutat Res 1998; 402: 279288.
  • 14
    Group TCGS. Efficacy and indications of ursodeoxycholic acid treatment for dissolving gallstones: a multicenter double-blind trial. Gastroenterology 1980; 78: 542548.
  • 15
    Fromm H. Ursodeoxycholic acid for adjuvant therapy with extracorporeal shock wave lithotripsy of gallstones. J Clin Gastroenterol 1988; 10: S1821.
  • 16
    Pauletzki J, Sailer C, Kluppelberg U, von Ritter C, Neubrand M, Holl J, et al. Gallbladder emptying determines early gallstone clearance after shock-wave lithotripsy. Gastroenterology 1994; 107: 14961502.
  • 17
    Calmus Y, Weill B, Ozier Y, Chereau C, Houssin D, Poupon R. Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology 1992; 103: 617621.
  • 18
    Rodrigues C, Fan G, Ma X, Kren B, Steer C. A novel role for ursodeoxycholic acid in nhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998; 101: 27902799.
  • 19
    Poupon R, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991; 324: 15481554.
  • 20
    Corpechot C, Carrat F, Poupon R, Poupon R. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002; 122: 652658.
  • 21
    Takano S, Ito Y, Yokosuka O, Ohto M, Uchiumi K, Hirota K, et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. HEPATOLOGY 1994; 20: 558564.
  • 22
    Shoda J, Ueda T, Ikegami T, Matsuzaki Y, Satoh S, Kano M, et al. Increased biliary group II phospholipase A2 and altered gallbladder bile in patients with multiple cholesterol stones. Gastroenterology 1997; 112: 20362047.
  • 23
    Kano M, Shoda J, Irimura T, Ueda T, Iwasaki R, Urasaki T, et al. Effects of long-term ursodeoxycholate administration on expression levels of secretory low-molecular-weight phospholipases A2 and mucin genes in gallbladders and biliary composition in patients with multiple cholesterol stones. HEPATOLOGY 1998; 28: 302313.
  • 24
    Ikegami T, Matsuzaki Y, Shoda J, Kano M, Hirabayashi N, Tanaka N. The chemopreventive role of ursodeoxycholic acid in azoxymethane- treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett 1998; 134: 129139.
  • 25
    Bouscarel B, Kroll S, Fromm H. Signal transduction and hepatocellular bile acid transport: cross talk between bile acids and second messengers. Gastroenterology 1999; 117: 433452.
  • 26
    Weinstein D. A single-step adsorption method for removal of lipoproteins and preparation of cholesterol-free serum. Circulation 1979; 59 and 60: II54.
  • 27
    Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156159.
  • 28
    Osborn L, Kunkel S, Nabel G. Tumor necrosis factor A and interleukin-1 stimulate human immunodeficiency virus enhancer by activation of the nuclear factor kB. Proc Natl Acad Sci U S A 1989; 86: 23362340.
  • 29
    Olivier JL, Fan Q, Salvat C, Ziari M, Kong L, Mangeney M, et al. Positive and negative hepatic regulation of the human type II phospholipase A2 gene. Biochemistry 1994; 33: 71347145.
  • 30
    Matsuzaki Y, Tanaka N, Osuga T, Aikawa T, Shoda J, Doi M, et al. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am J Gastroenterol 1990; 85: 1523.
  • 31
    Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited. HEPATOLOGY 2002; 36: 525531.
  • 32
    Tanaka H, Makino Y, Miura T, Hirano F, Okamoto K, Komura K, et al. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid: repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway: an SP1-like 5′-GACCACGCC-3′ sequence is critical for activity of the inflammatory phospholipase A2 promoter and binds several non-zinc finger proteins. J Immunol 1996; 156: 16011608.
  • 33
    Ikeda T, Sato C, Noguchi O, Kobayashi F, Tozuka S, Sakamoto S, et al. Improvement of peripheral blood lymphocyte subsets in primary biliary cirrhosis after ursodeoxycholic acid therapy. J Gastroenterol Hepatol 1996; 11: 366372.
  • 34
    Correia L, Podevin P, Borderie D, Verthier N, Montet JC, Feldmann G, et al. Effects of bile acids on the humoral immune response: a mechanistic approach. Life Sci 2001; 69: 23372348.
  • 35
    Powell AA, LaRue JM, Batta AK, Martinez JD. Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells. Biochem J 2001; 356: 481486.
  • 36
    Bouscarel B, Ceryak S, Gettys TW, Fromm H, Noonan F. Alteration of cAMP-mediated hormonal responsiveness by bile acids in cells of nonhepatic origin. Am J Physiol 1995; 268: G908G916.
  • 37
    Neuman MG, Shear NH, Bellentani S, Tiribelli C. Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells. Gastroenterology 1998; 115: 157166.
  • 38
    van Milligen de Wit AW, Kuiper H, Camoglio L, van Bracht J, Jones EA, Tytgat GN, et al. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis? Eur J Gastroenterol Hepatol 1999; 11: 129136.
  • 39
    Andreani M, Olivier JL, Berenbaum F, Raymondjean M, Bereziat G. Transcriptional regulation of inflammatory secreted phospholipases A(2). Biochim Biophys Acta 2000; 1488: 149158.
  • 40
    Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284: 13621365.
  • 41
    Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284: 13651368.
  • 42
    Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001; 276: 2885728865.
  • 43
    Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 2002; 23: 443463.
  • 44
    Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the Farnesoid X receptor. Mol Endocrinol 2003; 17: 259272.
  • 45
    Beck S, Lambeau G, Scholz-Pedretti K, Gelb MH, Janssen MJ, Edwards SH, et al. Potentiation of tumor necrosis factor alpha-induced secreted phospholipase A2 (sPLA2)-IIA expression in mesangial cells by an autocrine loop involving sPLA2 and peroxisome proliferator-activated receptor alpha activation. J Biol Chem 2003; 278: 2979929812.
  • 46
    Nakano T, Ohara O, Teraoka H, Arita H. Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression. J Biol Chem 1990; 265: 1274512748.
  • 47
    Massaad C, Paradon M, Jacques C, Salvat C, Bereziat G, Berenbaum F, et al. Induction of secreted type IIA phospholipase A2 gene transcription by interleukin-1beta. Role of C/EBP factors. J Biol Chem 2000; 275: 2268622694.
  • 48
    Miura T, Ouchida R, Yoshikawa N, Okamoto K, Makino Y, Nakamura T, et al. Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid. J Biol Chem 2001; 276: 4737147378.
  • 49
    Ogata K, Jin MB, Taniguchi M, Suzuki T, Shimamura T, Kitagawa N, et al. Attenuation of ischemia and reperfusion injury of canine livers by inhibition of type II phospholipase A2 with LY329722. Transplantation 2001; 71: 10401046.